



Cyclacel Pharmaceuticals, Inc.
Investor Relations Department
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: CYCC ¹

Last Trade:	1.65
Trade Time:	4:00 PM ET Aug 16, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.56 - 10.90
Volume	N/A
Market Cap. (\$M)	18.810
Shares Out (M)	11.400

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

We are a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- [Aug 9, 2017
Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results](#)
- [Aug 7, 2017
Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression](#)
- [Aug 2, 2017
Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results](#)
- [Jul 21, 2017
Cyclacel Announces Closing of \\$15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option](#)
- [Jul 19, 2017
Cyclacel Announces Pricing of \\$13.2 Million Underwritten Public Offering](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

- [Mar 31, 2017
Annual Report \(10-K\)](#)
- [Apr 12, 2017
Definitive Proxy Statement](#)
- [Aug 10, 2017
Quarterly Report \(10-Q\)](#)
- [May 12, 2017
Quarterly Report \(10-Q\)](#)
- [Nov 14, 2016
Quarterly Report \(10-Q\)](#)